Anatomy of the bony canal containing the middle meningeal artery for a vessel-sparing craniotomy in moyamoya disease
Listen to this summary
The authors aimed to investigate the anatomical features of bony canals containing the middle meningeal artery (MMA) to enhance vessel preservation during craniotomy in patients with moyamoya disease (MMD). They analyzed 175 dry skulls and cranial CT scans, revealing that the incidence of bony canals significantly increases with age and that MMD patients exhibit longer and wider canals compared to those with atherosclerotic cerebrovascular disease. This study underscores the importance of understanding MMA anatomy for surgical procedures involving bypass surgery in MMD.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.

More from Journal of neurosurgery
View all →Jun 5, 2026 · Journal of neurosurgery
Enhanced Recovery After Surgery in clipping surgery for unruptured cerebral aneurysm: prospective nonrandomized controlled trial
Jun 5, 2026 · Journal of neurosurgery
Harry J. Buncke to M. Gazi Yaşargil: a historical lesson in cross-specialty microsurgical innovation
More in Neurological Surgery
View all →Aug 6, 2026 · Lancet (London, England)
[<sup>177</sup>Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Aug 5, 2026 · The New England journal of medicine
Syncope
Jul 31, 2026 · Lancet (London, England)
Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 29, 2026 · Lancet (London, England)
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR


